Sanctuary Advisors LLC Has $466,000 Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Sanctuary Advisors LLC lifted its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 8.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,240 shares of the company’s stock after buying an additional 801 shares during the period. Sanctuary Advisors LLC’s holdings in Amphastar Pharmaceuticals were worth $466,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. TD Asset Management Inc grew its position in Amphastar Pharmaceuticals by 67.4% during the second quarter. TD Asset Management Inc now owns 1,691,569 shares of the company’s stock valued at $67,663,000 after purchasing an additional 680,976 shares in the last quarter. Epoch Investment Partners Inc. boosted its stake in shares of Amphastar Pharmaceuticals by 35.1% during the 2nd quarter. Epoch Investment Partners Inc. now owns 1,078,852 shares of the company’s stock valued at $43,154,000 after buying an additional 280,390 shares during the period. Geode Capital Management LLC grew its holdings in shares of Amphastar Pharmaceuticals by 1.5% during the 3rd quarter. Geode Capital Management LLC now owns 920,363 shares of the company’s stock valued at $44,674,000 after acquiring an additional 14,015 shares in the last quarter. American Century Companies Inc. increased its stake in shares of Amphastar Pharmaceuticals by 19.7% in the second quarter. American Century Companies Inc. now owns 740,408 shares of the company’s stock worth $29,616,000 after acquiring an additional 121,764 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in shares of Amphastar Pharmaceuticals by 84.6% during the second quarter. Millennium Management LLC now owns 738,748 shares of the company’s stock worth $29,550,000 after acquiring an additional 338,653 shares in the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on AMPH. StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Wells Fargo & Company initiated coverage on Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price target for the company. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $60.33.

Amphastar Pharmaceuticals Trading Down 0.3 %

Amphastar Pharmaceuticals stock opened at $38.17 on Friday. Amphastar Pharmaceuticals, Inc. has a one year low of $36.56 and a one year high of $65.92. The company’s fifty day moving average price is $45.79 and its two-hundred day moving average price is $44.50. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The company has a market capitalization of $1.84 billion, a price-to-earnings ratio of 12.72, a PEG ratio of 0.87 and a beta of 0.78.

Insider Transactions at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 5,000 shares of the business’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $48.80, for a total transaction of $244,000.00. Following the completion of the transaction, the director now owns 31,471 shares of the company’s stock, valued at $1,535,784.80. The trade was a 13.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Yakob Liawatidewi sold 5,214 shares of Amphastar Pharmaceuticals stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total value of $271,388.70. Following the completion of the transaction, the executive vice president now owns 74,938 shares in the company, valued at $3,900,522.90. The trade was a 6.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 41,533 shares of company stock worth $1,987,482. 27.10% of the stock is owned by corporate insiders.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.